Literature DB >> 29510828

In Reply.

Jörg Lauterberg.   

Abstract

Year:  2018        PMID： 29510828      PMCID： PMC5842350          DOI： 10.3238/arztebl.2018.0115

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN： 1866-0452            Impact factor:   5.594


× No keyword cloud information.
  3 in total

1.  Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.

Authors:  S Delaloge; D Pérol; C Courtinard; E Brain; B Asselain; T Bachelot; M Debled; V Dieras; M Campone; C Levy; W Jacot; V Lorgis; C Veyret; F Dalenc; J M Ferrero; L Uwer; P Kerbrat; A Goncalves; M A Mouret-Reynier; T Petit; C Jouannaud; L Vanlemmens; G Chenuc; T Guesmia; M Robain; C Cailliot
Journal:  Ann Oncol       Date:  2016-07-19       Impact factor: 32.976

Review 2.  The Range and Scientific Value of Randomized Trials.

Authors:  Stefan Lange; Stefan Sauerland; Jörg Lauterberg; Jürgen Windeler
Journal:  Dtsch Arztebl Int       Date:  2017-09-22       Impact factor: 5.594

3.  Biomedical research: increasing value, reducing waste.

Authors:  Malcolm R Macleod; Susan Michie; Ian Roberts; Ulrich Dirnagl; Iain Chalmers; John P A Ioannidis; Rustam Al-Shahi Salman; An-Wen Chan; Paul Glasziou
Journal:  Lancet       Date:  2014-01-08       Impact factor: 79.321
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.